The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 4) is the standard lexicon for grading adverse events (AEs) experienced by pediatric cancer patients in oncology trials. The current standard in clinical trials is that all AEs are graded and reported by clinicians.
Current methods for treating tumors include surgery, chemo-therapy and radiation therapy. Immune therapy is a fourth dimension to cancer therapy that has great potential, but this potential is as yet unmet. We propose that a powerful immune response can be generated against a tumor by targeting specific cells of the immune system. These immune cells are involved in the immune response to fight "foreign bodies". We have evidence that specialized receptors and cells can be stimulated in the patient to shape the ideal immune response against a tumor.
Priscilla is one of the strongest people her family knows. When she was diagnosed with leukemia, she needed to get to treatment and then a clinical trial far from home. ALSF's Travel For Care program got her there, and today Priscilla is cancer-free!
The National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 4) is the standard lexicon for grading adverse events (AEs) experienced by pediatric cancer patients in oncology trials. The current standard in clinical trials is that all AEs are graded and reported by clinicians.